Bionano Genomics, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
BNGO$1.16+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $2,990,000 | $9,173,000 |
| Investments | 16,279,000 | 302,000 |
| Accounts receivable, net | 5,200,000 | 4,752,000 |
| Inventory | 5,448,000 | 11,121,000 |
| Prepaid expenses and other current assets | 5,203,000 | 3,141,000 |
| Restricted cash and investments | 10,266,000 | 11,000,000 |
| Total current assets | 45,386,000 | 39,489,000 |
| Restricted cash | — | 400,000 |
| Property and equipment, net | 14,847,000 | 19,219,000 |
| Operating lease right-of-use assets | 3,217,000 | 1,804,000 |
| Finance lease right-of-use assets | 3,095,000 | 3,299,000 |
| Intangible assets, net | 4,345,000 | 9,705,000 |
| Other long-term assets | 2,694,000 | 2,754,000 |
| Total assets | $73,584,000 | $76,670,000 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,590,000 | $6,962,000 |
| Accrued expenses | 5,460,000 | 5,641,000 |
| Contract liabilities | 967,000 | 1,128,000 |
| Operating lease liability | 697,000 | 2,991,000 |
| Finance lease liability | 249,000 | 260,000 |
| Convertible debentures payable (at fair value) | 9,979,000 | 20,362,000 |
| Total current liabilities | 22,942,000 | 37,344,000 |
| Operating lease liability, net of current portion | 2,489,000 | 145,000 |
| Finance lease liability, net of current portion | 3,480,000 | 3,539,000 |
| Long-term contract liabilities | 249,000 | 267,000 |
| Total liabilities | $29,160,000 | $41,295,000 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and 2024 | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized at December 31, 2025 and 2024; 10,740,200 and 1,865,400 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1,000 | — |
| Additional paid-in capital | 764,026,000 | 728,573,000 |
| Accumulated deficit | (719,620,000) | (693,225,000) |
| Accumulated other comprehensive income | 17,000 | 27,000 |
| Total stockholders’ equity | 44,424,000 | 35,375,000 |
| Total liabilities and stockholders’ equity | $73,584,000 | $76,670,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.